Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8527603 | 0.87 | SRD5A1 (0.56) | SRD5A1SRD5A2 | |
| SCHEMBL915553 | 0.86 | SRD5A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL915495 | 0.86 | SRD5A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL917162 | 0.84 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL918096 | 0.84 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL917296 | 0.84 | SRD5A1 (0.51) | SRD5A1SRD5A2 | |
| SCHEMBL917701 | 0.84 | SRD5A1 (0.51) | SRD5A1SRD5A2 | |
| SCHEMBL8527387 | 0.83 | SRD5A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL917163 | 0.83 | SRD5A1 (0.50) | SRD5A1SRD5A2 | |
| SCHEMBL917025 | 0.83 | SRD5A1 (0.52) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6204273-B1 | TREATMENT OF ANDROGENIC SENSITIVE DISORDERS SUCH AS ACNE VULGARIS, SEBORRHEA, FEMALE HIRSUTISM, MALE PATTERN BALDNESS, AND BENIGN PROSTATIC HYPERPLASIA. | MERCK & CO., INC. | 2001-03-20 | — | — | US | disclosed |
| US-5910497-A | 16-pyrazinyl-substituted-4-aza-androstane 5-α-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1999-06-08 | — | — | US | disclosed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0724592-B1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5739137-A | 16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5719158-A | 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |